3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
3
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pathologic Complete Response
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
veliparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled